Silymarin in multiple Sclerosis

Phase 3

Recruiting

• Conditions: Therapeutic effect of silymarin.

• Registration Number: IRCT20171220037977N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

People with multiple sclerosis who go to Kashani hospital in Isfahan.
Patients taking CinnoVex for less than 1 year.

Exclusion Criteria

Patients with multiple sclerosis treated with other interferon beta drugs and immunosuppressive drugs
Patients who have already received CinnoVex and their treatment has been discontinued

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum interleukin level 10. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum interleukin level 17. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum interleukin level 23. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum interleukin level 35. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum interferon gamma. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum level of tumor growth factor beta. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.